398 related articles for article (PubMed ID: 2325710)
1. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy.
Luton JP; Cerdas S; Billaud L; Thomas G; Guilhaume B; Bertagna X; Laudat MH; Louvel A; Chapuis Y; Blondeau P
N Engl J Med; 1990 Apr; 322(17):1195-201. PubMed ID: 2325710
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
3. Adrenocortical tumors in children.
Ciftci AO; Senocak ME; Tanyel FC; Büyükpamukçu N
J Pediatr Surg; 2001 Apr; 36(4):549-54. PubMed ID: 11283875
[TBL] [Abstract][Full Text] [Related]
4. Adrenocortical carcinoma.
Decker RA; Kuehner ME
Am Surg; 1991 Aug; 57(8):502-13. PubMed ID: 1928992
[TBL] [Abstract][Full Text] [Related]
5. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane.
Wängberg B; Khorram-Manesh A; Jansson S; Nilsson B; Nilsson O; Jakobsson CE; Lindstedt S; Odén A; Ahlman H
Endocr Relat Cancer; 2010 Mar; 17(1):265-72. PubMed ID: 20026647
[TBL] [Abstract][Full Text] [Related]
6. Adrenocortical carcinoma: epidemiology and natural history.
Boscaro M; Fallo F; Barzon L; Daniele O; Sonino N
Minerva Endocrinol; 1995 Mar; 20(1):89-94. PubMed ID: 7651287
[TBL] [Abstract][Full Text] [Related]
7. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
Malandrino P; Al Ghuzlan A; Castaing M; Young J; Caillou B; Travagli JP; Elias D; de Baere T; Dromain C; Paci A; Chanson P; Schlumberger M; Leboulleux S; Baudin E
Endocr Relat Cancer; 2010 Sep; 17(3):797-807. PubMed ID: 20592067
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant mitotane treatment for adrenocortical carcinoma.
Terzolo M; Angeli A; Fassnacht M; Daffara F; Tauchmanova L; Conton PA; Rossetto R; Buci L; Sperone P; Grossrubatscher E; Reimondo G; Bollito E; Papotti M; Saeger W; Hahner S; Koschker AC; Arvat E; Ambrosi B; Loli P; Lombardi G; Mannelli M; Bruzzi P; Mantero F; Allolio B; Dogliotti L; Berruti A
N Engl J Med; 2007 Jun; 356(23):2372-80. PubMed ID: 17554118
[TBL] [Abstract][Full Text] [Related]
9. Adrenocortical carcinoma. Our experience.
Favia G; Lumachi F; Carraro P; D'Amico DF
Minerva Endocrinol; 1995 Mar; 20(1):95-9. PubMed ID: 7651289
[TBL] [Abstract][Full Text] [Related]
10. Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma.
Gonzalez RJ; Tamm EP; Ng C; Phan AT; Vassilopoulou-Sellin R; Perrier ND; Evans DB; Lee JE
Surgery; 2007 Dec; 142(6):867-75; discussion 867-75. PubMed ID: 18063070
[TBL] [Abstract][Full Text] [Related]
11. Clinical features and prognostic factors associated with adrenocortical carcinoma: Lahey Clinic Medical Center experience.
Tritos NA; Cushing GW; Heatley G; Libertino JA
Am Surg; 2000 Jan; 66(1):73-9. PubMed ID: 10651352
[TBL] [Abstract][Full Text] [Related]
12. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
[TBL] [Abstract][Full Text] [Related]
13. Mitotane treatment for adrenocortical carcinoma: an overview.
De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F
Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612
[TBL] [Abstract][Full Text] [Related]
14. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery.
Icard P; Chapuis Y; Andreassian B; Bernard A; Proye C
Surgery; 1992 Dec; 112(6):972-9; discussion 979-80. PubMed ID: 1455322
[TBL] [Abstract][Full Text] [Related]
15. [Adrenal carcinoma. Clinical and anatomopathological prognostic factors].
Boneschi M; Erba M; Beretta L; Miani S; Bortolani EM
Minerva Chir; 1998 Mar; 53(3):167-72. PubMed ID: 9617113
[TBL] [Abstract][Full Text] [Related]
16. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry.
Michalkiewicz E; Sandrini R; Figueiredo B; Miranda EC; Caran E; Oliveira-Filho AG; Marques R; Pianovski MA; Lacerda L; Cristofani LM; Jenkins J; Rodriguez-Galindo C; Ribeiro RC
J Clin Oncol; 2004 Mar; 22(5):838-45. PubMed ID: 14990639
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly.
Daffara F; De Francia S; Reimondo G; Zaggia B; Aroasio E; Porpiglia F; Volante M; Termine A; Di Carlo F; Dogliotti L; Angeli A; Berruti A; Terzolo M
Endocr Relat Cancer; 2008 Dec; 15(4):1043-53. PubMed ID: 18824557
[TBL] [Abstract][Full Text] [Related]
18. [Adrenocortical carcinoma and its treatment with mitotane. Description of a case].
Parma A; D'Agnolo B
Minerva Med; 1991 Dec; 82(12):883-8. PubMed ID: 1780099
[TBL] [Abstract][Full Text] [Related]
19. [Mitotane in the treatment of adrenal carcinoma].
Sane T
Duodecim; 2010; 126(17):2040-6. PubMed ID: 21053521
[TBL] [Abstract][Full Text] [Related]
20. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
